Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profiles
- 1 February 2012
- journal article
- research article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 22 (2) , 123-131
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 50 references indexed in Scilit:
- Bipolar disorder and metabolic syndrome: An international perspectiveJournal of Affective Disorders, 2010
- Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcomeBipolar Disorders, 2010
- Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicityTrends in Endocrinology & Metabolism, 2010
- Metabolic Syndrome in Patients Enrolled in a Clinical Trial of Aripiprazole in the Maintenance Treatment of Bipolar I DisorderThe Journal of Clinical Psychiatry, 2010
- Obesity and Onset of Significant Depressive SymptomsThe Journal of Clinical Psychiatry, 2009
- Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and DiabetesDiabetes Care, 2009
- Atypical Antipsychotic Usage-Related Higher Serum Leptin Levels and Disabled Lipid Profiles in Euthymic Bipolar PatientsNeuropsychobiology, 2006
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for PennsylvaniansBipolar Disorders, 2005
- Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 2005